| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 01 Jul 2025 | 0001055947 |
| BIOTECHNOLOGY VALUE FUND L P | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer | 01 Jul 2025 | 0000918923 |
| BVF I GP LLC | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 01 Jul 2025 | 0001803805 |
| BIOTECHNOLOGY VALUE FUND II LP | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer | 01 Jul 2025 | 0001102444 |
| BVF II GP LLC | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 01 Jul 2025 | 0001803806 |
| Biotechnology Value Trading Fund OS LP | Director, Other* | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS | BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 01 Jul 2025 | 0001660683 |
| BVF Partners OS Ltd. | Director, Other* | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS | Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President | 01 Jul 2025 | 0001660684 |
| BVF GP HOLDINGS LLC | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer | 01 Jul 2025 | 0001803809 |
| BVF INC/IL | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | BVF Inc., By: /s/ Mark N. Lampert, President | 01 Jul 2025 | 0001056807 |
| LAMPERT MARK N | Director, Other* | 44 MONTGOMERY STREET, 40TH FLOOR, SAN FRANCISCO | /s/ Mark N. Lampert | 01 Jul 2025 | 0001233840 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KYMR | Common Stock, $0.0001 par value | Purchase | $6,274,576 | +142,604 | +5.4% | $44.00 | 2,798,795 | 30 Jun 2025 | Direct | F1, F2, F6 |
| transaction | KYMR | Common Stock, $0.0001 par value | Purchase | $5,094,452 | +115,783 | +5.5% | $44.00 | 2,219,858 | 30 Jun 2025 | Direct | F1, F3, F6 |
| transaction | KYMR | Common Stock, $0.0001 par value | Purchase | $2,586,320 | +58,780 | +20% | $44.00 | 353,412 | 30 Jun 2025 | Direct | F1, F4, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KYMR | Stock Option (Right to Buy) | Award | $0 | +16,000 | $0.000000 | 16,000 | 25 Jun 2025 | Common Stock, $0.0001 par value | 16,000 | $46.47 | See footnote | F5, F7 | |
| holding | KYMR | Pre-Funded Warrants to Purchase Common Stock | 201,546 | 25 Jun 2025 | Common Stock, $0.0001 par value | 201,546 | $0.000100 | Direct | F1, F2, F8 | |||||
| holding | KYMR | Pre-Funded Warrants to Purchase Common Stock | 156,742 | 25 Jun 2025 | Common Stock, $0.0001 par value | 156,742 | $0.000100 | Direct | F1, F3, F8 | |||||
| holding | KYMR | Pre-Funded Warrants to Purchase Common Stock | 550,425 | 25 Jun 2025 | Common Stock, $0.0001 par value | 550,425 | $0.000100 | Direct | F1, F2, F8 | |||||
| holding | KYMR | Pre-Funded Warrants to Purchase Common Stock | 375,856 | 25 Jun 2025 | Common Stock, $0.0001 par value | 375,856 | $0.000100 | Direct | F1, F3, F8 | |||||
| holding | KYMR | Pre-Funded Warrants to Purchase Common Stock | 52,733 | 25 Jun 2025 | Common Stock, $0.0001 par value | 52,733 | $0.000100 | Direct | F1, F4, F8 | |||||
| holding | KYMR | Stock Option (Right to Buy) | 16,000 | 25 Jun 2025 | Common Stock, $0.0001 par value | 16,000 | $31.20 | See footnote | F5, F9 | |||||
| holding | KYMR | Stock Option (Right to Buy) | 40,127 | 25 Jun 2025 | Common Stock, $0.0001 par value | 40,127 | $20.00 | See footnote | F5, F9 | |||||
| holding | KYMR | Stock Option (Right to Buy) | 20,063 | 25 Jun 2025 | Common Stock, $0.0001 par value | 20,063 | $49.10 | See footnote | F5, F9 | |||||
| holding | KYMR | Stock Option (Right to Buy) | 12,000 | 25 Jun 2025 | Common Stock, $0.0001 par value | 12,000 | $14.18 | See footnote | F5, F9 | |||||
| holding | KYMR | Stock Option (Right to Buy) | 12,000 | 25 Jun 2025 | Common Stock, $0.0001 par value | 12,000 | $27.67 | See footnote | F5, F9 |
| Id | Content |
|---|---|
| F1 | This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. |
| F2 | Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. |
| F3 | Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. |
| F4 | Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. |
| F5 | Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. |
| F6 | Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share. |
| F7 | The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
| F8 | The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire. |
| F9 | The shares subject to the option have fully vested. |
For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.